AMAG Pharmaceuticals Reports First Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Raymond James Downgrades AMAG Pharmaceuticals (AMAG) to Market Perform
May 4, 2016 6:39 AM EDTRaymond James downgraded AMAG Pharmaceuticals (NASDAQ: AMAG) from Outperform to Market Perform and removed its price target (prior $55.00).
For an analyst ratings summary and ratings history on AMAG Pharmaceuticals click here. For more ratings news on AMAG Pharmaceuticals click here.
Shares of AMAG Pharmaceuticals closed at $22.03 yesterday.
... MoreAMAG Pharma (AMAG) Misses Q1 EPS by 17c; Reiterates Outlook
May 3, 2016 7:07 AM EDTAMAG Pharma (NASDAQ: AMAG) reported Q1 EPS of $0.94, $0.17 worse than the analyst estimate of $1.11. Revenue for the quarter came in at $117.6 million versus the consensus estimate of $124.83 million.
We are off to a strong start in 2016, achieving goals on our next-generation program for Makena, including the commercial launch of our new single-dose, preservative-free formulation, as well as solidifying an important new strategic relationship to further expand access to FDA-approved Makena, said William Heiden, AMAGs chief... More
